Showing results (1311-1320 of 1,391) with videos related to

Sort By:
Pageof 140
Biochemistry and Molecular Biology International|May 1, 1997
Complete sequence of the UPP gene encoding uracil phosphoribosyltransferase from Mycobacterium bovis BCGJ K Kim, J H Kim, S H Lee, et al.
Clinical & Translational Immunology|June 29, 2023
Robust immunity to influenza vaccination in haematopoietic stem cell transplant recipients following reconstitution of humoral and adaptive immunityWuji Zhang, Louise C Rowntree, Ramona Muttucumaru, et al.
Journal of Hepatology|January 10, 2024
Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liverTallulah S Andrews, Diana Nakib, Catia T Perciani, et al.
Vaccine|June 17, 2025
Genetic markers of enhanced functional antibody responses to COVID-19 vaccinationRuth A Purcell, L Carissa Aurelia, Lilith F Allen, et al.
Journal of Virology|March 15, 2013
Structures of the compact helical core domains of feline calicivirus and murine norovirus VPg proteinsEoin N Leen, K Y Rex Kwok, James R Birtley, et al.
Cancer|May 10, 2022
Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092-22092 STRASS trialRick Haas, Jean-Jacques Stelmes, Facundo Zaffaroni, et al.
JCI Insight|January 9, 2025
Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccinesWen Shi Lee, Kevin J Selva, Jennifer Audsley, et al.
Human Gene Therapy|July 21, 2018
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope VaccineHannah Mary Cheeseman, Suzanne Day, Leon Robert McFarlane, et al.
British Journal of Cancer|June 10, 2010
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinomaK K Y Cham, J H E Baker, K S Takhar, et al.
Science Translational Medicine|December 15, 2021
A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancerAndrew W Chung, Kartik Anand, Ann C Anselme, et al.
Pageof 140